A new drug for Inflammatory Bowel Disease is hitting the global market. In mid-May Entyvio (vedolizumab) injection was approved by the U.S. FDA. In the last few days, it has also been approved for use in the European Union by the European Commission (EC). Entyvio is being ushered in by Japan-based Takeda Pharmaceuticals (1).
There are approximately 620,000 Americans and 2.2 million Europeans dealing with IBD. These patients deal with significant pain and reduction in quality of life. This new medication could provide significant relief for patients who did not have an adequate response to the traditional treatments.
Entyvio is a new type of biologic therapy called an integrin receptor antagonist. It works to block the migration of inflammatory cells by preventing specific integrin receptors on those cells from reacting with a specific protein on the cells in the walls of blood vessels. This is different from other biologic medications (like Humira and Remicaid), that block Tumer Nucrosis Factor (TNF), to reduce symptoms (2).
The side effects for Entyvio are similar to other biologica and can include joint pain, headache, nausea, infections and other issues. Talk with your physician about whether the risks of the medication are outweighed by the benefit and what side effects to monitor.
This is a promising addition to the IBD treatment arsenal. Hopefully this will prove to provide relief for many patients who have not found relief with previous treatments.
Published On: June 10, 2014